7-Day Nonbismuth-Containing Concomitant Therapy Achieves a High Eradication Rate for Helicobacter pylori in Taiwan

被引:8
作者
Kao, Sung-Shuo [1 ]
Chen, Wen-Chi [1 ]
Hsu, Ping-I [1 ]
Lai, Kwok-Hung [1 ]
Yu, Hsien-Chung [1 ]
Cheng, Hui-Hwa [2 ]
Peng, Nan-Jing [3 ]
Lin, Chiun-Ku [1 ]
Chan, Hoi-Hung [1 ]
Tsai, Wei-Lun [1 ]
Wang, Huay-Min [1 ]
Tsai, Tzung-Jiun [1 ]
Lin, Kung-Hung [1 ]
Tsay, Feng-Woei [1 ]
机构
[1] Kaohsiung Vet Gen Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung 813, Taiwan
[2] Kaohsiung Vet Gen Hosp, Dept Pathol, Kaohsiung 813, Taiwan
[3] Kaohsiung Vet Gen Hosp, Dept Nucl Med, Kaohsiung 813, Taiwan
关键词
SEQUENTIAL THERAPY; TRIPLE THERAPY; QUADRUPLE THERAPY; INFECTION; METAANALYSIS; OMEPRAZOLE; MANAGEMENT; DIAGNOSIS; REGIMEN; UREASE;
D O I
10.1155/2012/463985
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background. Ten-day concomitant therapy achieves a high eradication rate in Taiwan. Whether shortening the duration of concomitant therapy can still keep a high eradication rate remains unclear. Aim. To assess the eradication rate of 7-day pantoprazole-containing concomitant therapy in Taiwan and to investigate factors influencing the eradication outcome. Methods. From March 2008 to March 2012, 319 H. pylori-infected patients receiving a 7-day pantoprazole-containing concomitant regimen (pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 7 days) were included. Patients were asked to return at the second week to assess drug compliance and adverse effects. Repeated endoscopy or urea breath test was performed at 8 weeks after the end of eradication therapy. Results. The eradication rates according to intention-to-treat and per-protocol analyses were 93.7% (299/319) and 96.4% (297/308), respectively. Adverse events occurred in 13.2% (42/319) of the patients. The compliance rate was 98.4% (314/319). Multivariate analysis disclosed that poor compliance was the only independent factor influencing the efficacy of anti-H. pylori therapy with an odds ratio of 0.073 (95% confidence interval, 0.011-0.483). Conclusion. 7-day concomitant therapy achieved a very high eradication rate for H. pylori infection in Taiwan. Drug compliance was the only clinical factor influencing treatment efficacy.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial
    Tai, Wei-Chen
    Liang, Chih-Ming
    Kuo, Chung-Mou
    Huang, Pao-Yuan
    Wu, Cheng-Kun
    Yang, Shih-Cheng
    Kuo, Yuan-Hung
    Lin, Ming-Tsung
    Lee, Chen-Hsiang
    Hsu, Chien-Ning
    Wu, Keng-Liang
    Hu, Tsung-Hui
    Chuah, Seng-Kee
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (06) : 1718 - 1724
  • [32] The Efficacy of Moxifloxacin-Containing Triple Therapy after Standard Triple, Sequential, or Concomitant Therapy Failure for Helicobacter pylori Eradication in Korea
    Chung, Kwang Hyun
    Lee, Dong Ho
    Jin, Eunhyo
    Cho, Yuri
    Seo, Ji Yeon
    Kim, Nayoung
    Jeong, Sook Hyang
    Kim, Jin Wook
    Hwang, Jin-Hyeok
    Shin, Cheol Min
    [J]. GUT AND LIVER, 2014, 8 (06) : 605 - 611
  • [33] Response to: Comment on "Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients"
    Ribaldone, Davide Giuseppe
    Saracco, Giorgio
    Pellicano, Rinaldo
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2016, 2016
  • [34] Helicobacter pylori Infection: Sequential Therapy Followed by Levofloxacin-Containing Triple Therapy provides a Good Cumulative Eradication Rate
    Manfredi, Marco
    Bizzarri, Barbara
    de'Angelis, Gian Luigi
    [J]. HELICOBACTER, 2012, 17 (04) : 246 - 253
  • [35] Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
    Tai, Wei-Chen
    Chiu, Chien-Hua
    Liang, Chih-Ming
    Chang, Kuo-Chin
    Kuo, Chung-Mou
    Chiu, Yi-Chun
    Wu, Keng-Liang
    Hu, Ming-Luen
    Chou, Yeh-Pin
    Chiou, Shue-Shian
    Chiu, King-Wah
    Kuo, Chung-Huang
    Hu, Tsung-Hui
    Lin, Ming-Tsung
    Chuah, Seng-Kee
    [J]. GASTROENTEROLOGY RESEARCH AND PRACTICE, 2013, 2013
  • [36] An optimized clarithromycin-free 14-day triple therapy for Helicobacter pylori eradication achieves high cure rates in Uruguay
    Dacoll, Cristina
    Sanchez-Delgado, Jordi
    Baiter, Henia
    Pazos, Ximena
    Di Pace, Maria
    Sandoya, Gabriela
    Cohen, Henry
    Calvet, Xavier
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (07): : 447 - 454
  • [37] Eradication of H pylori infection in a rural population: One-day quadruple therapy versus 7-day triple therapy
    Meinhard Classen
    [J]. World Journal of Gastroenterology, 2006, (24) : 3915 - 3918
  • [38] Eradication of H pylori infection in a rural population:: One-day quadruple therapy versus 7-day triple therapy
    Zhang, Lian
    Shen, Lin
    Ma, Jun-Ling
    Pan, Kai-Feng
    Liu, Wei-Dong
    Li, Jie
    Xiao, Shu-Dong
    Lin, San-Ren
    Classen, Meinhard
    You, Wei-Cheng
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2006, 12 (24) : 3915 - 3918
  • [39] Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance
    Cosme, Angel
    Lizasoan, Jacobo
    Montes, Milagrosa
    Tamayo, Esther
    Alonso, Horacio
    Mendarte, Usua
    Martos, Maider
    Fernandez-Reyes, Maria
    Saraqueta, Cristina
    Bujanda, Luis
    [J]. HELICOBACTER, 2016, 21 (01) : 29 - 34
  • [40] Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area
    Georgopoulos, Sotirios D.
    Xirouchakis, Elias
    Martinez-Gonzales, Beatrice
    Zampeli, Evanthia
    Grivas, Elias
    Spiliadi, Charikleia
    Sotiropoulou, Maria
    Petraki, Kalliopi
    Zografos, Kostantinos
    Laoudi, Fotini
    Sgouras, Dionysios
    Mentis, Andreas
    Kasapidis, Panagiotis
    Michopoulos, Spyros
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2016, 32 : 84 - 90